Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Industry, Academia Join In California
by Michael McCoy
February 17, 2014
| A version of this story appeared in
Volume 92, Issue 7
MedImmune, the biologics arm of AstraZeneca, has entered a three-year research collaboration with the Clinical & Translational Science Institute at the University of California, San Francisco. The pact will focus on the institute’s Catalyst Awards program, which solicits applications from university scientists who want to move their research beyond the bench. The partners say they will work together to move the most promising research projects forward. MedImmune says the collaboration should benefit its R&D as well as AstraZeneca’s small-molecule drug discovery efforts.
You might also like...
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X